[
1. Zhou, Y, Geng, Z, Wang, X, Huang, Y, Shen, L, Wang, Y. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 2020;36:e3223.10.1002/dmrr.322331642583
]Search in Google Scholar
[
2. McNeill AM, Davies G, Kruger E, Kowal S, Reason T, Ejzykowicz F, et al. Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: A systematic literature review and network meta-analysis. Diabetes Ther. 2019;10(2):473-91.10.1007/s13300-019-0566-x643724630689140
]Search in Google Scholar
[
3. Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, et al. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(4):1018-26.10.1111/dom.1362030565382
]Search in Google Scholar
[
4. Deacon CF, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes – a review and meta analysis. Diabetes Obes Metab. 2012;14(8):762-7.10.1111/j.1463-1326.2012.01603.x22471248
]Search in Google Scholar
[
5. Scheen AJ. Reduction in HbA1C with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1C: A systematic review of randomized controlled trials. Diabetes Metab. 2020;46(3):186-96.10.1016/j.diabet.2020.01.00232007623
]Search in Google Scholar
[
6. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30-7.10.1111/dom.1217423803146
]Search in Google Scholar
[
7. Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015;29(8):1295-303.10.1016/j.jdiacomp.2015.07.01126365905
]Search in Google Scholar
[
8. Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Sci Rep. 2019;9(1):19351. doi:10.1038/s41598-019-55524-w10.1038/s41598-019-55524-w692036831852920
]Search in Google Scholar
[
9. McHugh KR, De Vore AD, Mentz RJ, Edmonston D, Green JB, Hernandez AF. The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes. Clin Cardiol. 2018;41(9):1259-67.10.1002/clc.23054649010430125365
]Search in Google Scholar
[
10. Wu S, Cipriani A, Yang Z, Yang J, Cai T, Xu Y, et al. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis. Expert Opin Drug Saf. 2018;17(3):243-9.10.1080/14740338.2018.142482629320889
]Search in Google Scholar
[
11. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.10.1136/bmj.d5928
]Search in Google Scholar
[
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.10.1016/0197-2456(86)90046-2
]Search in Google Scholar
[
13. Rosenstock J, Marquard J, Laffel L, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in Type 1 diabetes: The EASE Trials. Diabetes Care. 2018;41(12):2560-256.10.2337/dc18-174930287422
]Search in Google Scholar
[
14. Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928-35.10.1111/dom.12494474502826080652
]Search in Google Scholar
[
15. Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina S, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab. 2018;20(9): 2190-9.10.1111/dom.13351609935829766633
]Search in Google Scholar
[
16. Perkins B, Cherney D, Partridge H. et al. Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care. 2014;37(5):1480-3.10.2337/dc13-233824595630
]Search in Google Scholar
[
17. Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in participants with type 1 diabetes mellitus. Circ. 2014;129(5):587-97.10.1161/CIRCULATIONAHA.113.00508124334175
]Search in Google Scholar
[
18. Mathieu C, Eeckhout B. et al. Empagliflozin in type 1 diabetes. Diabetes Metab Syndr Obes. 2019;12:1555-61.10.2147/DMSO.S194688670981331686876
]Search in Google Scholar
[
19. Llano A, McKay G, Fisher M. SGLT inhibitors for people with type 1 diabetes. Practical Diabetes. 2019;36:3.10.1002/pdi.2222
]Search in Google Scholar
[
20. Danne T, Garg S, Peters A, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in participants with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;18:2316.
]Search in Google Scholar
, 